<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Delta variant &#8211; India Chron</title>
	<atom:link href="https://indiachron.com/tag/delta-variant/feed/" rel="self" type="application/rss+xml" />
	<link>https://indiachron.com</link>
	<description></description>
	<lastBuildDate>Sat, 03 Jul 2021 08:19:08 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://indiachron.com/wp-content/uploads/2026/02/favicon-4-150x150.png</url>
	<title>Delta variant &#8211; India Chron</title>
	<link>https://indiachron.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Covaxin is 77.8% effective, gives 65.2% Protection against Delta variant, says Bharat Biotech</title>
		<link>https://indiachron.com/nation/covaxin-is-77-8-effective-gives-65-2-protection-against-delta-variant-says-bharat-biotech/</link>
		
		<dc:creator><![CDATA[Himanjali Mahanta]]></dc:creator>
		<pubDate>Sat, 03 Jul 2021 08:09:39 +0000</pubDate>
				<category><![CDATA[Nation]]></category>
		<category><![CDATA[Bharat Biotech]]></category>
		<category><![CDATA[COVAXIN]]></category>
		<category><![CDATA[Delta variant]]></category>
		<category><![CDATA[Effectiveness]]></category>
		<guid isPermaLink="false">https://indiachron.com/covaxin-is-77-8-effective-gives-65-2-protection-against-delta-variant-says-bharat-biotech</guid>

					<description><![CDATA[Phase-III trials of Covaxin, made by Hyderabad’s Bharat Biotech, showed it was 93.4% effective against severe symptomatic Covid-19, the firm…]]></description>
										<content:encoded><![CDATA[<p>Phase-III trials of Covaxin, made by Hyderabad’s Bharat Biotech, showed it was 93.4% effective against severe symptomatic Covid-19, the firm claimed on Saturday.</p>
<p>The data demonstrated 65.2% protection against the Delta variant, first identified in India. The Delta variant had led to a surge in infections in April and May, and the world’s highest daily death tolls.</p>
<p>It further showed effectiveness of an 77.8% against symptomatic Covid-19 in the trial. On Saturday, India reported 44,111 new Covid cases and 738 deaths. The recovery rate further jumped to 97.06% with 2,29,05,779 recoveries.</p>
<p>Last month, vaccine maker AstraZeneca also said its vaccine was effective against the Delta and Kappa variants, citing a study.</p>
<p>India has been administering the AstraZeneca vaccine, made domestically by the Serum Institute of India, which plans to step up monthly production from July to nearly 100 million doses.</p>
<p>Bharat Biotech now estimates it will make 23 million doses a month. The Phase-III data came as Ocugen Inc, which is co-developing Covaxin with Bharat Biotech for the US market, prepares to file a request for full US approval.</p>
<p>India, with a tally of 30.45 million infections, is the second most affected nation after the United States, with 33 million. The south Asian nation’s death toll has now crossed 400,000.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
